Cargando…

17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA

BACKGROUND: Both preclinical and human research suggest that cannabidiol (CBD) has antipsychotic properties. This study assessed the safety and effectiveness of CBD in patients with schizophrenia. METHODS: Patients with schizophrenia (n=88) were randomized to receive CBD (1000 mg/day) or placebo alo...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGuire, Philip, Robson, Philip, Cubała, Wiesław, Vasile, Daniel, Morrison, Paul, Barron, Rachel, Taylor, Adam, Wright, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887970/ http://dx.doi.org/10.1093/schbul/sby014.065

Ejemplares similares

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
por: Ranganathan, Mohini, et al.
Publicado: (2018)

O1.7. PROTEOMIC ANALYSIS OF BLOOD BASED SAMPLES FROM THE OPTiMiSE (OPTIMIZATION OF TREATMENT AND MANAGEMENT OF SCHIZOPHRENIA IN EUROPE) STUDY POINT TOWARDS COMPLEMENT PATHWAY PROTEIN CHANGES
por: Föcking, Melanie, et al.
Publicado: (2018)

S171. ALTERED WHITE MATTER CONNECTIVITY IN PATIENTS WITH SCHIZOPHRENIA USING PUBLIC NEUROIMAGING DATA FROM SCHIZCONNECT
por: Joo, Sung Woo, et al.
Publicado: (2018)

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
por: Chesney, Edward, et al.
Publicado: (2020)

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
por: Chesney, Edward, et al.
Publicado: (2020)

17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD)
por: Crippa, Jose Alexandre, et al.
Publicado: (2018)

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

F171. ALTERED DIFFUSIVITY IN THE BRAIN OF PATIENTS WITH SCHIZOPHRENIA: A DIFFUSION WEIGHTED MAGNETIC RESONANCE IMAGING STUDIES WITH PUBLIC NEUROIMAGING DATA
por: Jo, Young Tak, et al.
Publicado: (2018)

171. The Impact of COVID-19 on Healthcare-Associated Infections
por: Baker, Meghan A, et al.
Publicado: (2021)

F228. EFFECTIVENESS OF PALIPERIDONE PALMITATE VS OTHER LONG-ACTING INJECTABLE (LAI) ANTIPSYCHOTICS – AN ELECTRONIC CASE REGISTER STUDY
por: Patel, Rashmi, et al.
Publicado: (2018)

T150. REAL-TIME FMRI NEUROFEEDBACK TO DOWN-REGULATE SUPERIOR TEMPORAL GYRUS ACTIVITY IN PATIENTS WITH SCHIZOPHRENIA AND AUDITORY HALLUCINATIONS: A PROOF-OF-CONCEPT STUDY
por: Orlov, Natasza, et al.
Publicado: (2018)

Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease
por: Singh, Kritika, et al.
Publicado: (2022)

O3.5. TESTING THE DOPAMINE HYPOTHESIS OF PSYCHOSIS USING POSITRON EMISSION TOMOGRAPHIC IMAGING IN FIRST EPISODE BIPOLAR AFFECTIVE DISORDER AND SCHIZOPHRENIA
por: Jauhar, Sameer, et al.
Publicado: (2018)

PM367. Effect of cannabidiol on cognition in a maternal immune activation (poly IC) model of schizophrenia
por: Osborne, Ashleigh L., et al.
Publicado: (2016)

O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA
por: McQueen, Grant, et al.
Publicado: (2018)

171. Diagnostic stewardship to limit repeat plasma cytomegalovirus viral load testing
por: Trirattanapikul, Akeatit, et al.
Publicado: (2022)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

CAM 17.1--a new diagnostic marker in pancreatic cancer.
por: Gansauge, F., et al.
Publicado: (1996)

S17.1 Issues and concerns in the management of healthcare-associated pneumonia in the Philippines
Publicado: (2005)

17.1 Examining the Impact of COVID-19 on Adolescents With Eating Disorders
por: Spettigue, Wendy, et al.
Publicado: (2021)

O4.2. HERITABILITY AND CORRELATION TO SCHIZOPHRENIA SPECTRUM DISORDER OF GLUTAMATE AND OTHER NEUROMETABOLITE LEVELS IN ANTERIOR CINGULATE AND LEFT THALAMUS: A REGISTER BASED MAGNETIC RESONANCE TWIN STUDY
por: Legind, Christian, et al.
Publicado: (2018)

PS171. Dissociable Effects of Social Stress on Exploratory and Exploitative Reasoning Across Age
por: Kumar, Dilip, et al.
Publicado: (2016)

171. Impact of Limiting Antimicrobial Indication Options in a Pediatric Electronic Health Record
por: Shapiro, Craig, et al.
Publicado: (2018)

T101. ENRICHING PSYCHOTIC DISORDER CLASSIFICATION USING NATURAL LANGUAGE PROCESSING
por: Patel, Rashmi, et al.
Publicado: (2018)

171. Rising Rates of Gram-Negative Bacilli Blood Stream (GNB-BSI) Infection in Adults
por: Johnson, Leonard B, et al.
Publicado: (2019)

13.2 CANNABIDIOL AS AN ANTIPSYCHOTIC DRUG
por: Guimaraes, Francisco, et al.
Publicado: (2018)

Cannabidiol (CBD) and Insomnia : Literature review
por: Gutierrez Higueras, T., et al.
Publicado: (2022)

CANNABIDIOL- PROVOKES OR TREATS ANXIETY DISORDERS?
por: Arshad, H., et al.
Publicado: (2023)

171 Impact of Rapid Bloodstream Pathogen Identification in Hospitalized Patients
por: Maslonka, Matthew, et al.
Publicado: (2014)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

At PS171 (ASTERIX)
Publicado: (1983)

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
por: McCutcheon, Robert A., et al.
Publicado: (2023)

171. Short-course Antimicrobial Therapy for Paediatric Respiratory Infections (SAFER): a multicentre, Randomized, Controlled, Blinded, Noninferiority Trial
por: Pernica, Jeffrey, et al.
Publicado: (2020)

AB171. Targeting Ninjurin-1 for future therapy of erectile dysfunction
por: Yin, Guo Nan, et al.
Publicado: (2014)

Correction: Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
por: McCutcheon, Robert A., et al.
Publicado: (2023)

T171. REDUCED FRONTAL CORTICAL THICKNESS AND SURFACE IN A 10 YEARS FOLLOW-UP OF EARLY ONSET PSYCHOSIS
por: Ilzarbe, Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4437ffm19lt4qb5f75jn571qr9